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Drug-induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of
indications or withdrawal of drugs. Some nonsteroidal anti-inflammatory drugs (NSAIDs) were withdrawn from the market be-
cause of serious hepatotoxicity. We estimated the risk of acute and serious liver injury associated with the use of nimesulide and
other NSAIDs, with a prevalence of use greater than or equal to 5%.
METHODS
This is a multicentre case–control study carried out in nine Italian hospitals fromOctober 2010 to January 2014. Cases were adults, with
a diagnosis of acute liver injury. Controls presented acute clinical disorders not related to chronic conditions, not involving the liver.
Adjusted odds ratio (ORs) with 95% confidence interval (CI) were calculated initially with a bivariate and then multivariate analysis.
RESULTS
We included 179 cases matched to 1770 controls. Adjusted OR for acute serious liver injury associated with all NSAIDs was 1.69,
95% CI 1.21–2.37. Thirty cases were exposed to nimesulide (adjusted OR 2.10, 95% CI 1.28–3.47); the risk increased according
to the length of exposure (OR> 30 days: 12.55, 95% CI 1.73–90.88) and to higher doses (OR 10.69, 95% CI 4.02–28.44). Risk of
hepatotoxicity was increased also for ibuprofen, used both at recommended dosages (OR 1.92, 95% CI 1.13–3.26) and at higher
doses (OR 3.73, 95% CI 1.11–12.46) and for ketoprofen ≥ 150 mg (OR 4.65, 95% CI 1.33–10.00).
CONCLUSION
Among all NSAIDs, nimesulide is associated with the higher risk, ibuprofen and high doses of ketoprofen are also associated with a
modestly increased risk of hepatotoxicity.© 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd
on behalf of The British Pharmacological Society.
DOI:10.1111/bcp.12938
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dium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Acute liver injury associated to NSAIDsWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Drug-induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for failure of approval,
restriction of indications or withdrawal of drugs.
• Some NSAIDs were withdrawn from the market because of serious hepatotoxicity.
• Nimesulide is an NSAID suspended from the market in several countries because of high frequency of hepatotoxicity.
WHAT THIS STUDY ADDS
• These findings add new elements to the available data on incidence of drug-induced hepatotoxicity.
• There is an association between the use of some NSAIDs and risk of acute serious liver injury in Italian patients.
• Among commonly used anti-inflammatory drugs, nimesulide is associated with a slight increase of risk, which raises with time
exposure and dosage. For ibuprofen and high dosage of ketoprofen, an increased risk was also found.Introduction
Drug-induced liver injury (DILI) is a condition that can symp-
tomatically mimic most kinds of acute and chronic liver pa-
thologies and is the most common cause of acute liver
failure both in the USA [1, 2] and in Europe [3, 4]. DILI is con-
sidered among the most serious adverse drug reactions
(ADRs) and represents the main cause of discontinuing the
development of new drugs at early stages and the most fre-
quent reason for refusal to approve, restriction of indications
or withdrawal of drugs by regulatory agencies [5–7].
Since the diagnosis of this condition is not simple and
pre-marketing studies are unable to detect all possible hepatic
ADRs, little is known about the incidence of DILI in the gen-
eral population and the available data come from spontane-
ous reports and few epidemiologic studies [8]. Björnsson
and colleagues defined the incidence of DILI by prospectively
examining a population-based cohort in Iceland: 96 cases of
DILI were identified between 2010 and 2011, with an annual
incidence of 19.1 cases per 100 000 inhabitants (95% CI,
1.54–23.3) [9]. Another French population-based study
reported an incidence of 13.9 cases per 100 000 inhabitants
per year, with a 6%mortality rate [10]. Two studies from Swe-
den and the UK, in contrast, found a lower incidence, that is
2.3 and 2.4 per 100 000 inhabitants per year respectively [11,
12]. Liver injury can be associated with several drug classes,
most commonly antibiotics, antifungal, antituberculosis,
antiepileptic and NSAIDs [13].
NSAIDs represent one of themost widely used drug classes
in the world and the most commonly used analgesics [14].
The major adverse effects of NSAIDs are gastrointestinal,
cardiovascular and renal injuries, which are well documented
[15, 16]; hepatotoxicity is a rare ADR, usually not dose
related, but serious and even fatal [15, 17–21].
Several NSAIDs were withdrawn from the market because
of hepatic ADRs (bromfenac, ibufenac, benoxaprofen,
droxicam, pirprofen, fenclofenac and, more recently,
lumiracoxib); others, such as nimesulide, were never
marketed in some countries or withdrawn in others. In 2002
Finland and Spain suspended the marketing of this drug be-
cause of the high frequency of hepatotoxicity [22, 23]. Conse-
quently, the European Medicines Agency (EMA) started an
evaluation procedure on nimesulide safety and in 2004 it
concluded that the benefit–risk profile of this drug was
favourable. However, the EMA’s Committee for MedicinalProducts for Human Use (CHMP) recommended restriction
of nimesulide indications to the treatment of acute pain,
symptomatic treatment of painful osteoarthritis and pri-
mary dysmenorrhea, and withdrawal from the market of
the 200 mg pharmaceutical formulation, restricting the
maximal drug dosage at 100 mg twice a day; nimesulide
was also contraindicated in children under 12 years of age
[24]. In May 2007 the Irish medicines regulatory authority
decided to suspend the marketing authorization for sys-
temic nimesulide-containing medicines owing to new in-
formation regarding cases of fulminant hepatic failure
requiring liver transplantation, which led the EMA to a fur-
ther review process [25]. Also in this case the risk–benefit
balance of nimesulide remained positive, although the
EMA restricted the duration of therapy to 15 days, and rec-
ommended the drug only as a second-line treatment. Two
years later, in 2009, nimesulide was withdrawn from the
market in Argentina as well [26]. In 2012 the EMA com-
pleted a review of the safety and effectiveness of systemic
medicines containing nimesulide and concluded that, com-
pared with other NSAIDs, nimesulide was associated with
an increased risk of liver toxicity and its risk–benefit ratio
remained positive for its use in acute pain and dysmenor-
rhea but not for osteoarthritis [27]. An important contribu-
tion to the debate on the hepatotoxicity of nimesulide was
provided by the Italian study published by Traversa and
colleagues, which concluded that although the risk of liver
injury in patients taking nimesulide and other NSAIDs is
small, such risk is higher for nimesulide [28]. Another
study, conducted in Italy in 2010, showed that NSAIDs
were more commonly associated with DILI and 70% of
the observed cases were attributable to nimesulide [29].
The aim of the Drug-Induced Liver Injury in Italy (DILI-
IT) study was to estimate the risk of acute and serious liver
injury associated with the use of nimesulide and other
NSAIDs with a prevalence of use greater than or equal to
5% of the total number of drugs taken by the study popu-
lation. The hepatotoxic risk associated with paracetamol
was assessed as well.
Furthermore, the study assessed the risk of acute and se-
rious liver injury induced by amoxicillin and amoxicillin
with clavulanic acid, macrolides, antidepressants and
statins.
Here, we present the results of the main analysis on the
risk of liver injury associated to nimesulide and NSAIDs.Br J Clin Pharmacol (2016) 82 238–248 239
M. Donati et al.Methods
Study population
We conducted a multicentre case–control study where cases
and controls were all recruited among hospital patients in
Italy, from October 2010 to January 2014.
Nine hospitals located in four regions representative of
the North (Veneto and Emilia Romagna), Central (Tuscany)
and South (Campania) of Italy participated in the study; the
population covered by the hospitals involved is approxi-
mately 4938 700 inhabitants (8.3% of the Italian popula-
tion). Patients eligible were those visited by hospital
physicians participating in the study.
Cases were defined as all patients aged 18 or over ad-
mitted with a primary diagnosis of acute liver injury. Ac-
cording to the definition of DILI [13] and in accordance
with the hepatologists involved in the study, we used the
following criteria for case definition: (1) increase of 2 N
(N is the upper limit of normal range and each activity is
expressed as a multiple of N) for alanine aminotransferase
(ALT), aspartate aminotransferase (AST) serum activity in
patients who presented symptoms or not; (2) increase of
1.5 N of alkaline phosphatase (AP) associated with an in-
crease of ALT or AST and/or total bilirubin in patients with
or without symptoms.
Ten hospital controls were selected consecutively for each
case, matched according to gender and age (+/ 5 years), and
to hospital and time from admission (within 2 months).
Controls were patients with a minimum age of 18 years,
admitted for acute clinical disorders not related to chronic
conditions, not involving the liver (with normal liver enzyme
values) and without specific indications or contraindications
for NSAID use. The selected admission diagnoses were: non-
alcohol-related trauma or fracture, acute appendicitis, bowel
obstruction, intestinal perforation, acute pancreatitis, pneu-
monia in patients without risk factors, pneumothorax
without previous chronic obstructive bronchitis or chronic
obstructive pulmonary disease, renal colic, euthyroid nodule,
bite, accidental injuries or burns, foreign bodies, abdominal
gestation/fallopian tube rupture or miscarriage, testicular
torsion and umbilical hernia.
Both cases and controls were excluded if the patients
had a diagnosis of viral hepatitis, biliary abnormality, his-
tory of alcohol abuse, autoimmune disease, genetic and
metabolic disorders which may determine liver injury, a
low alpha-1-antitrypsin level and an abnormal phenotype
(that may suggest disease associated with a deficiency of
this protein), Wilson’s disease, HIV/AIDS, hepatic neoplasia
or liver metastasis, systemic lupus erythematosus, mush-
room poisoning and drug addiction or detoxification treat-
ment in the last 3 months; finally, patients who were not
resident in the study areas were also excluded (primary
exclusion criteria). Patients who were discharged or died
before interview and those refusing the interview or unable
to answer were also excluded (secondary exclusion criteria).
A panel of experts (External Advisory Board) was
established to monitor the appropriateness of inclusion
and exclusion criteria for cases and controls; they repre-
sented also an important support in the debate about the
problems that emerged during patient recruitment.240 Br J Clin Pharmacol (2016) 82 238–248Exposure to drugs
Exposure to drugs was defined as any use in the 90 days prior
to the index day (ID) [30]. For each case, the ID was consid-
ered as the onset day of the liver damage symptoms or the
date corresponding to the first available abnormal value of
liver enzyme tests. For controls, the ID was taken as the onset
day of any symptom relating to the disease for which the pa-
tient was selected as a control.
For NSAIDs with a prevalence of use >5% and for paracet-
amol, different periods of use/non-use were compared and
cumulative time of exposure was defined as less than or equal
to 15 days, between 15 and 30 days and greater than 30 days.
Moreover, the average daily dose of each NSAID and paracet-
amol was calculated for each patient and two dose categories
were considered on the basis of the corresponding DDD (de-
fined daily dose) [31]. The number of exposed patients ac-
cording to time and dose categories was calculated.
Information retrieval
Drug exposure was investigated by trained monitors by face-
to-face interview using a standardized questionnaire (Case
Report Form, CRF). Before the interview, the aim of the study
was explained to patients and written informed consent was
obtained. The CRF covered information regarding demo-
graphic data, medical history, coexisting illnesses, lifestyle
and dietary habits, alcohol, tobacco and coffee intake and
use of herbal products. Data concerning the diagnosis of liver
injury and the evolution of the disease were collected from
medical records. Clinical records were also used to evaluate
the diagnoses of the controls.
To ensure that drug history was as complete as possible
and to reduce recall bias, after an open question about pre-
vious use of drugs, patients were questioned about a list of
common symptoms often prompting use of medicines of
interest. Patients were also shown a photographic collec-
tion reproducing the packaging of main medicinal prod-
ucts concerned (most used NSAIDs, amoxicillin and
amoxicillin with clavulanic acid, macrolides, antidepres-
sants and statins).
Statistical analysis
Data are presented as mean values (SD) and frequencies (%).
Odds ratios (OR) and their 95% confidence intervals (95%
CI) have been calculated bymeans of a conditional logistic re-
gression for matched case–control groups, using the Stata Sta-
tistical Software version 11.0 (StataCorp, College Station, TX,
2009). OR has been computed initially with a bivariate and
then multivariate analysis, to assure that the risk estimates
for liver injury and use of drugs were appropriately adjusted
for possible confounders and effect modifiers. Covariates in-
cluded were: smoking, alcohol, body mass index (BMI), liver
comorbidities (hepatitis, gallstones, liver cirrhosis, hepatic
nodules and other hepatic diseases), heart comorbidities
(stroke, angina pectoris, heart failure, arrhythmia and cardiac
surgery), and coprescribed drugs (other NSAIDs, paracetamol,
amoxicillin, amoxicillin/clavulanic acid, macrolides, antide-
pressants and statins). There was a negligible amount of miss-
ing data (all found on control group) for: BMI (less than 1%;
11 subjects out of 1770), alcohol consumption (less than
1%; 3 subjects out of 1770), and smoking (less than 1%; 2
Cases
n = 2232
Cases excluded (n = 2028):
- Biliary tract disorders (39%)
- Cancer (22%)
- Viral hepatitis (20%)
- Chronic liver disease (13%)
- Alcoholism (3%)
- Other causes (3%)
Cases included
n = 204
Not interviewed (n = 25):
- Discharge before interview (52%)
- Inability to answer (36%)
- Death (8%)
Controls
n = 3059
Matching criteria :
- Age
- Sex
- Date of admission
- Centre of admission
Acute liver injury associated to NSAIDssubjects out of 1770). Therefore no methods to account for
missing data have been used and complete case analyses have
been performed. The effect of gender and age on risk of liver
injury among NSAID users have been evaluated using an un-
conditional logistic regression.
The sample size for the first primary objective (relative
risk of nimesulide-induced liver injury) was estimated as-
suming a minimal detectable risk (OR) of 2.0 with alpha
0.05 and at a power of 80%, and a prevalence of
nimesulide use of 8%. Given these assumptions, 163 cases
and 1630 controls (matched case–control ratio 1:10) were
required. This sample size was considered adequate even
with a slightly different prevalence in the control popula-
tion (range: 5–10%): this would detect an odds ratio rang-
ing from 2.28 (alpha 0.05; power: 80%) for a 5%
prevalence to an odds ratio of 1.91 (alpha 0.05; power:
80%) for a 10% prevalence. The latter proportion has been
found (184 nimesulide users among 1770 matched con-
trols) in the present study. The Pass 11 statistical software,
version 11.0.7, was used for these calculations.- Refusal to participate (4%)
Cases analysed
n = 179
Controls matched
n = 1770Ethical considerations
The study was approved by the Independent Ethics Commit-
tee (IEC) of Verona Hospital (principal investigator and coor-
dinating centre) and consecutively notified to the IECs of
participating centres.Figure 1
Flow diagram of patients included in the studyResults
Population
Overall, 2232 patients with diagnosis of acute serious liver in-
jury were recorded; of those, 2028 were not included in the
study, according to the primary exclusion criteria. The 204 in-
cident cases resulted in an annual incidence of DILI of 4.1
cases per 100 000 inhabitants. Subsequently, 25 other cases
were excluded on the basis of secondary criteria. Therefore,
the analysis was performed on 179 cases. In the same period,
3059 patients were selected and interviewed as possible con-
trols. From this sample, 1770 patients were matched to the
179 cases, according to gender, age, centre and time from ad-
mission (Figure 1). Controls included in the analysis were en-
rolled for the following diagnosis: trauma or fracture (46%),
acute appendicitis (15%), gastrointestinal disorders (14%), re-
spiratory disorders (13%) and other acute events (12%).
Table 1 shows the baseline characteristics of recruited
patients. Women were slightly more represented than
men (58% vs 42%). Controls were found to be slightly
more overweight compared to cases and they consumed
alcohol (as current drinkers) and tobacco (as former
smokers) more frequently than cases. Again, in a slightly
greater number of cases compared to controls liver and
heart co-morbidities were observed. Cases used more drugs
than controls (with an average number of drugs of 5.0 and
2.6 respectively). Nevertheless, except for drug consump-
tion, there were no significant differences between cases
and controls. The profile of cases and controls utilizing
NSAIDs did not differ from that of the whole study
population.Risk of acute liver injury related to NSAIDs and
nimesulide
Table 2 shows the OR estimates of acute serious liver injury
associated with all NSAIDs: during the three months before
the index day, 97 out of 179 cases (corresponding to 54%)
and 737 out of 1770 controls (42%) were exposed to NSAIDs.
The annual incidence of DILI induced by NSAIDs (N-DILI)
was two cases per 100 000 inhabitants and the OR, adjusted
for all covariates considered in the analysis, was 1.69 (95%
CI, 1.21–2.37).
Taking into account sex and age, we did not find any sta-
tistically significant differences in the risk of DILI. Table 3 re-
ports the acute serious liver injury OR for single NSAIDs with
a prevalence of use greater than or equal to 5% and for para-
cetamol. Apart from ASA, which is also used in cardiovascular
disorders, nimesulide was the most used NSAID in the study
period (prevalence of use of 11.1%). Paracetamol too was
largely utilized in our patients, with a prevalence of use of
16.7%.
As shown in Table 3, 30 cases (17%) and 184 controls
(10%) were exposed to nimesulide resulting in an adjusted
risk of acute and serious liver injury of 2.10 (95% CI, 1.28–
3.47). Besides nimesulide, only ibuprofen was associated to
a statistically significant increased risk of liver damage, with
an adjusted OR equal to 1.92 (95% CI, 1.13–3.26). The well-
known paracetamol-associated hepatotoxicity is confirmed
by three-fold increase of risk (adjusted OR 2.97, 95% CI
2.09–4.21).Br J Clin Pharmacol (2016) 82 238–248 241
Table 2
Odds Ratios (OR) and 95% confidence intervals (95% CI) of acute serious liver injury associated with NSAIDs (sex and age related analysis)
Drug No. (%) of cases No. (%) of controls OR (95% CI) ORAdg (95% CI)†
NSAIDs* 97 (54) 737 (42) 1.71 (1.23–2.36) 1.69 (1.21–2.37)
Sex
Male 43 (44) 306 (42) 1 1
Female 54 (56) 431 (58) 0.89 (0.57–1.40) 0.71 (0.42–1.19)
Age
<45 46 (47) 293 (40) 1 1
45–65 29 (30) 225 (30) 0.82 (0.48–1.38) 1.21 (0.66–2.20)
>65 22 (23) 219 (30) 0.64 (0.36–1.12) 0.75 (0.36–1.56)
*NSAIDs with at least one case included nimesulide, acetylsalicylic acid (ASA), ibuprofen, ketoprofen, diclofenac, celecoxib, etoricoxib, naproxen,
flurbiprofen, piroxicam, indomethacin, and dexibuprofen. †See methods sections for details of adjustment.
Table 1
Baseline characteristics of patients in study population and in NSAID users
Study population NSAID users
Characteristic
Cases
n = 179
Controls
n = 1770 P value
Cases
NSAIDs n = 97
Controls
NSAIDs n = 737
P value
NSAIDs
Sex, n (%) — —
Male 75 (42) 750 (42) 43 (44) 306 (42)
Female 104 (58) 1020 (58) 54 (56) 431 (58)
Age (years), mean (SD) 52.8 (19.4) 53.3 (19.3) 0.74 49.4 (18.7) 51.6 (19.4) 0.29
Schooling level (years),
mean (SD)
10.5 (4.8) (n = 174) 10.5 (5.2) (n = 1721) 0.86 10.6 (4.5) (n = 96) 10.7 (4.7) (n = 714) 0.84
BMI, mean (SD) 24.8 (4.6) 25.3 (4.4) (n = 1759) 0.15 25.0 (5.1) 25.3 (4.7) 0.56
Alcohol, n (%) 0.58 0.62
Current drinker 102 (57) 1072 (61) 59 (61) 481 (65)
Former drinker 8 (4) 67 (4) 3 (3) 26 (4)
Non-drinker 69 (39) 628 (35) 35 (36) 227 (31)
Smoke, n (%) 0.59 0.38
Current smoker 45 (25) 445 (25) 32 (33) 202 (27)
Former smoker 26 (15) 311 (18) 14 (14) 141 (19)
Non-smoker 108 (60) 1012 (57) 51 (53) 392 (53)
Co-morbidities, n (%)
Liver diseases 19 (10) 146 (8) 0.26 15 (15) 99 (13) 0.64
Heart diseases 30 (17) 237 (13) 0.21 17 (17) 140 (19) 0.78
Drugs, mean (SD) 5.0 (3.2) 2.6 (2.4) <0.001 5.1 (3.0) 3.4 (2.3) <0.001
M. Donati et al.During the study four fatal cases of hepatitis were ob-
served. For three patients the physicians established a possi-
ble relation between hepatitis and drug treatment
(metolazone, rifaximin and amiodarone); the fourth patient242 Br J Clin Pharmacol (2016) 82 238–248was suffering from many concomitant diseases and he was
treated with several drugs, some of which are known to be as-
sociated with disorders of the hepatobiliary system (e.g.
valproic acid, phenobarbital, lansoprazole, carbamazepine).
Table 3
Odds ratios (OR) and 95% confidence intervals (95% CI) of acute serious liver injury associated with all NSAIDs and paracetamol
Drug (prevalence of use) No. (%) of cases No. (%) of controls OR (95% CI) ORAdg (95% CI)*
ASA (13.5) 31 (17) 253 (14) 1.30 (0.85–2.00) 1.54 (0.95–2.48)
Nimesulide (11.1) 30 (17) 184 (10) 1.88 (1.20–2.95) 2.10 (1.28–3.47)
Ketoprofen (10.7) 19 (11) 177 (10) 0.98 (0.57–1.68) 1.10 (0.60–2.00)
Ibuprofen (8.1) 25 (14) 170 (10) 1.59 (0.98–2.57) 1.92 (1.13–3.26)
Diclofenac (5.1) 12 (7) 85 (5) 1.48 (0.77–2.84) 1.50 (0.74–3.06)
Paracetamol (16.7) 69 (39) 309 (17) 3.27 (2.32–4.59) 2.97 (2.09–4.21)
*See methods sections for details of adjustment.
Acute liver injury associated to NSAIDsBoth this patient and that associated withmetolazone also re-
ceived low-dose ASA. No deaths were observed among the
controls.
Risk of acute liver injury related to time of
exposure and dose
Except for ASA (mainly used as an antiplatelet drug), NSAIDs
and paracetamol seem to be used for a short period of time
not exceeding 15 days, suggesting, therefore, an occasional
consumption.
The analysis showed an increased risk of liver injury re-
lated to the length of exposure to nimesulide (OR > 30 days:
12.55; 95% CI, 1.73–90.88) and paracetamol (OR > 30 days:
18.36; 95% CI, 4.60–73.34). Considering exposures shorter
than 15 days, nimesulide, ibuprofen and paracetamol are as-
sociated with a statistically significant adjusted odd ratio
(OR 1.89; 95% CI, 1.12–3.20; OR 1.89; 95% CI, 1.09–3.26;
OR 2.66; 95% CI, 1.83–3.88 respectively). Due to the low
number of cases, time-related analysis was not completely
possible for ketoprofen (Table 4).
No single NSAID was associated with a significant risk of
hepatotoxicity when taken at doses equal to or less than
recommended, while for paracetamol this condition is pres-
ent (Table 5). Exposure to higher doses of nimesulide was as-
sociated with a six-fold increase in risk of acute liver injury
(adjusted OR 10.69; 95% CI, 4.02–28.44 vs adjusted OR
1.55; 95% CI, 0.89–2.70 for recommended dose). Risk of hep-
atotoxicity was increased also for patients receiving higher
doses of ketoprofen (adjusted OR 4.65; 95% CI, 1.33–10.00)
and ibuprofen (adjusted OR 3.73; 95% CI, 1.11–12.46). The
number of cases and controls considered in the time of expo-
sure and dosage analysis may not correspond to the total, due
to missing data on duration of therapy and doses.Discussion
The annual incidence of DILI observed in this study was 4.1
cases per 100000 inhabitants and about half of these patients
received NSAIDs (giving an annual incidence of N-DILI of two
cases per 100000 inhabitants). These data are partially in agree-
ment with the evidence available until now: the incidence of
DILI reported from Swedish and English studies confirms ourresults [11, 12]; however, these retrospective studies found a
six to eight times lower incidence than the population-based
studies from Björnsson and colleagues and Sgro and colleagues
[9, 10]. Probably, these results reflect some differences between
the studymethodology that should be taken into account: first,
the studies which revealed the lower incidence of DILI used da-
tabases as primary sources of information, while the studies by
Sgro and Björnsson were based on active participation of physi-
cians and specialists which, in turn, recruited patients in a hos-
pital and/or outpatient setting. Moreover, the first of these two
studies considered only DILI in an outpatient setting while the
second observed the incidence of DILI in both in- and outpa-
tients. Also the period of patient recruitment varied among
studies, ranging from 2 to 10 years [9–11]. Our findings about
the incidence of N-DILI corresponds to what is reported in the
literature: inmost studies these data are rather uniform, ranging
from one to nine cases per 100000 persons exposed to NSAIDs
[32].
Considering the association between acute and serious
liver injury and NSAID utilization, our results showed that
there is a small risk of acute and serious liver injury in NSAID
users and that nimesulide and ibuprofen are associated with a
higher risk of hepatotoxicity than other NSAIDs.
In general, the available evidence reports that DILI is
more likely to occur in females and in elderly people and this
is also supported in some NSAID-associated hepatotoxicity
analysis. Traversa and colleagues [28] reported that risk of
liver injury was increased among elderly people (age over or
equal to 75 years) and a case–control study in primary care
in a southwestern area of France showed a significant
association between hepatic ADRs and NSAID use only in
women [18]. At variance with what such studies reported, in
our population no significant differences were associated with
patients’ gender and age with regard to risk of liver injury.
Although hepatotoxicity is an adverse effect of NSAID
class considered worldwide as rare, serious liver damage is
the main adverse event which caused some NSAIDs to be
withdrawn from the market and the epidemiological data
about the individual NSAID risk of liver injury is still diver-
gent [15, 28, 33].
Population-based studies on liver toxicity induced by
NSAIDs indicated a higher risk for diclofenac; however, in
these studies the rate of serious hepatic adverse events, hospi-
talization or death was low [12, 32, 34, 35]. In contrast, in aBr J Clin Pharmacol (2016) 82 238–248 243
Table 4
Odds ratios (OR) and 95% confidence intervals (95% CI) of acute serious liver injury associated with different time of exposure of NSAIDs and
paracetamol
DRUG
Time of exposure No. (%) of cases No. (%) of controls OR (95% CI) ORAdg (95% CI)*
NIMESULIDE
<15 days 25 (13.97) 176 (9.94) 1.66 (1.03–2.68) 1.89 (1.12–3.20)
15–30 days 2 (1.12) 5 (0.28) 4.82 (0.92–25.34) 4.89 (0.80–30.00)
>30 days 3 (1.68) 3 (0.17) 16.05 (2.60–98.94) 12.55 (1.73–90.88)
ASA
<15 days 7 (3.93) 76 (4.30) 0.93 (0.42–2.08) 1.06 (0.45–2.50)
15–30 days 1 (0.56) 1 (0.06) 10.60 (0.66–169.75) 6.31 (0.37–106.38)
>30 days 22 (12.36) 173 (9.79) 1.40 (0.83–2.35) 1.66 (0.93–2.96)
KETOPROFEN
<15 days 18 (10.06) 173 (9.77) 0.94 (0.54–1.64) 1.05 (0.57–1.93)
15–30 days 1 (0.56) 2 (0.11) 4.97 (0.45–54.87) 6.55 (0.56–76.66)
>30 days 0 (0) 2 (0.11) NA NA
IBUPROFEN
<15 days 23 (12.85) 162 (9.16) 1.52 (0.92–2.50) 1.89 (1.09–3.26)
15–30 days 1 (0.56) 4 (0.23) 2.57 (0.29–23.05) 2.53 (0.26–24.69)
>30 days 1 (0.56) 3 (0.17) 3.46 (0.36–33.29) 2.58 (0.25–26.95)
DICLOFENAC
<15 days 10 (5.59) 74 (4.19) 1.42 (0.70–2.87) 1.35 (0.63–2.92)
15–30 days 1 (0.56) 3 (0.17) 3.47 (0.36–33.40) 4.23 (0.40–45.07)
>30 days 1 (0.56) 4 (0.23) 2.58 (0.29–23.13) 4.66 (0.49–44.15)
PARACETAMOL
<15 days 61 (34.08) 286 (16.16) 3.08 (2.14–4.43) 2.66 (1.83–3.88)
15–30 days 3 (1.68) 7 (0.40) 6.01 (1.51–23.89) 5.25 (1.21–22.82)
>30 days 5 (2.79) 6 (0.34) 14.78 (3.90–56.00) 18.36 (4.60–73.34)
*See methods sections for details of adjustment
M. Donati et al.survey on suspected drug-induced liver fatalities reported to
the WHO database (in 88% of the cases the reporting country
was the United States), diclofenac was the only NSAID impli-
cated among the top 20 causes and a systematic review re-
ported the prevalence of hospitalization as 22.4 per 100 000
patient-year of diclofenac exposure [36, 37]. These data devi-
ate from our results, which have not revealed any risk of acute
and serious liver damage associated with the use of
diclofenac. Regulatory actions, restrictions and, in some
countries, withdrawal from the market have been applied to
nimesulide, another NSAID possibly implicated in hepato-
toxicity. The first cases of serious or fatal liver injury in Fin-
land and subsequently in Spain and Ireland led to the
withdrawal of the drug in these countries; however, the last
EMA evaluation concluded that the risk–benefit profile re-
mains favourable and recommended restrictions in its use
[27]. These decisions were supported by epidemiological244 Br J Clin Pharmacol (2016) 82 238–248studies confirming that nimesulide was associated with
only a small increase in risk [28, 38]. Our study corrobo-
rates this conclusion, providing further information on
time of exposure and dosage. In most cases nimesulide
was administered at recommended time of exposure and
daily dosages (time lower than 15 days and dosage lower
than 200 mg) and in these conditions the risk seems to
be very low; however, an exponential increase of hepato-
toxicity risk is observed with increasing duration of treat-
ment and with higher dosages.
The increased risk of liver injury associated with
nimesulide is of particular concern in Italy since the use of
this drug is still widespread, despite the restriction in indica-
tions (only acute pain and dysmenorrhea) and treatment du-
ration. In fact, according to national drug utilization data,
nimesulide was the fourth most prescribed NSAID in 2013,
with a consumption of 3.1 DDD/1000 inhabitants/day [39].
Table 5
Odds ratios (OR) and 95% confidence intervals (95% CI) of acute serious liver injury associated with different doses of NSAIDs and paracetamol
DRUG
Dose No. (%) of cases No. (%) of controls OR (95% CI) ORAdg (95% CI)†
NIMESULIDE
<200 mg 21 (11.73) 172 (9.72) 1.41 (0.85–2.35) 1.55 (0.89–2.70)
≥200 mg 9 (5.03) 12 (0.68) 8.03 (3.36–9.22) 10.69 (4.02–28.44)
ASA
<300 mg 21 (11.73) 168 (9.49) 1.35 (0.80–2.27) 1.46 (0.82–2.58)
≥300 mg 10 (5.59) 85 (4.80) 1.22 (0.62–2.43) 1.70 (0.81–3.54)
KETOPROFEN
<150 mg 10 (5.62) 142 (8.02) 0.67 (0.34–1.34) 0.73 (0.35–1.54)
≥150 mg 8 (4.49) 19 (1.07) 3.29 (1.35–8.04) 4.65 (1.33–10.00)
IBUPROFEN
<1200 mg 20 (11.24) 155 (8.76) 1.45 (0.86–2.43) 1.71 (0.97–3.02)
≥1200 mg 4 (2.23) 15 (0.85) 2.62 (0.82–8.32) 3.73 (1.11–12.46)
DICLOFENAC
<100 mg 5 (2.79) 30 (1.69) 1.69 (0.64–4.48) 2.13 (0.77–5.91)
≥100 mg 3 (1.68) 25 (1.41) 1.19 (0.35–4.09) 1.21 (0.30–4.85)
PARACETAMOL
<3000 mg 42 (23.46) 265 (14.97) 2.22 (1.48–3.15) 2.04 (1.35–3.09)
≥3000 mg I26 (14.52) I44 (2.49) I7.80 (4.53–13.43) I6.31 (3.56–11.20)
†See methods sections for details of adjustment
Acute liver injury associated to NSAIDsFurthermore, our research found a significant risk of se-
rious and acute liver damage associated with ibuprofen and
the dose-related analysis showed that this risk increased
with the dose administered. This finding was quite unex-
pected, as the current literature reports a very low liver tox-
icity incidence for ibuprofen [28, 32, 33]. Some case reports
of liver damage associated with ibuprofen were described in
the scientific literature [40, 41] and some information
emerged from recent observational studies and reviews
which investigated DILI and the risk of hepatotoxicity in
patients exposed to NSAIDs [38, 42]. A case series from
Riley and colleagues also suggested that ibuprofen may
increase the risk of liver injury in patients with hepatitis
C [43], though we were not able to confirm this observa-
tion as, people suffering from hepatitis C were excluded
from our study. Nevertheless, our result for ibuprofen
should be taken into consideration as ibuprofen is the
most commonly used NSAID worldwide and among these
drugs it is associated with the lower risk of gastrointestinal,
cardiovascular and renal serious events.
In the present study, ketoprofen was associated with a sig-
nificant increased risk of acute and serious liver injury only at
dosages higher than recommended. We did not find any ad-
ditional specific information on ketoprofen hepatotoxicity
and our data strengthen the importance of using all NSAIDs
within the therapeutic dosages.Hepatotoxicity of high doses of paracetamol is a well-
documented risk, but the question whether therapeutic use
causes acute liver failure is still open, as several individual fac-
tors, such as concomitant alcohol use or abuse, concurrent
medications, genetic factors and nutritional status, can influ-
ence the susceptibility of patients to paracetamol hepatotox-
icity [44]. A moderate risk of acute liver injury associated with
paracetamol at usual analgesic doses has been reported in
some documented cases and in observational studies [45, 46].
A limitation of our study was related to the number of re-
cruited cases, which was lower than expected; in fact, the
actual incidence of liver injury events involving hospitaliza-
tion was lower than reported in the literature, probably due
to relevant recent changes in hospital practice (e.g. increased
outpatient management of liver injury). The precision of risk
estimates of serious liver injury for the time and dosage anal-
ysis is affected by the low number of recruited cases and this is
reflected in the calculated CI values. Moreover, our analysis
did not provide information about the characterization of
the liver damage.
The main strength of our case–control analysis is the pre-
cision and accuracy in the selection of patients: we excluded
other possible causes of hepatic disease to prevent a potential
bias of misdiagnosis and we considered all the variables that
could influence the risk of developing liver damage. Defini-
tion of inclusion and exclusion criteria was made inBr J Clin Pharmacol (2016) 82 238–248 245
M. Donati et al.collaboration with a panel of expert hepatologists. Our find-
ings are also representative of the Italian situation: the study
was conducted in four regions distributed in the Northern,
Central and Southern Italy and the population covered by
this area represents about 10% of the national population.
Furthermore, patients were recruited over a long period of
time, subsequent to the measures taken by the European
and Italian Regulatory Agency, which allowed us to evaluate
the effects of these regulatory measures in the clinical prac-
tice. Finally, quality control and assurance measures were im-
plemented to ensure that procedures were shared by all
centres and data were reasonably valid and coherent as re-
garding both cases controls. Quality assurance measures were
applied to the interview technique, to recruitment and man-
agement of the patients, and finally to the quality of data en-
try in the database. The interview was standardized and the
questionnaire tested in a pilot phase to ensure the readability
of its content. The monitors were trained before and during
the study and appropriate explanations were integrated into
the training plan and monitor manuals. Quality control and
assurance measures were set for all centres by the Coordinat-
ing Centre.
Our findings confirm that hepatotoxicity represents a rare
but serious adverse drug reaction and that NSAIDs are associ-
ated with an increased risk.
Among NSAIDs, nimesulide is associated with the higher
risk, whereas ibuprofen and high doses of ketoprofen are also
associated with a modestly increased risk of hepatotoxicity.
The results on nimesulide are especially relevant to Italy,
where, despite regulatory restrictions by the EMA, the drug
is still largely utilized causing a risk of hepatotoxicity that in-
creases with dosage and time of exposure.
Finally, the issue of liver injury induced by NSAIDs at dos-
age exceeding the DDD should not be underestimated, as ex-
tensive evidence is available showing that these drugs are
often used inappropriately [47]. In fact, several NSAIDs are
currently worldwide available on the market as over-the-
counter (OTC) drugs, not requiring any medical prescription
and with a management of treatment duration and dosage
performed only by the patient, without any medical supervi-
sion. The consequence of this attitude is the total lack of med-
ical assessment of the possible risks and contraindications,
duration and dose of NSAID treatment, which can lead to a
greater number of side effects, sometimes serious and
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